RT Journal Article
T1 Artificial Intelligence: an emerging tool for studying drug-induced liver injury.
A1 Niu, Hao
A1 Álvarez-Álvarez, Ismael
A1 Chen, Minjun
K1 Inteligencia artificial en medicina
K1 Proceso en lenguaje natural (Informática)
K1 Hígado -  Efectos de los medicamentos
K1 Hígado - Enfermedades
K1 Aprendizaje automático (Inteligencia artificial)
K1 Hepatotoxicidad
AB Drug-induced liver injury (DILI) is a complex and potentially severe adverse reaction to drugs, herbal products or dietary supplements. DILI can mimic other liver diseases clinical presentation, and currently lacks specific diagnostic biomarkers, which hinders its diagnosis. In some cases, DILI may progress to acute liver failure. Given its public health risk, novel methodologies to enhance the understanding of DILI are crucial. Recently, the increasing availability of larger datasets has highlighted artificial intelligence (AI) as a powerful tool to construct complex models. In this review, we summarise the evidence about the use of AI in DILI research, explaining fundamental AI concepts and its subfields. We present findings from AI-based approaches in DILI investigations for risk stratification, prognostic evaluation and causality assessment and discuss the adoption of natural language processing (NLP) and large language models (LLM) in the clinical setting. Finally, we explore future perspectives and challenges in utilising AI for DILI research.
PB Wiley
YR 2025
FD 2025-02-21
LK https://hdl.handle.net/10630/38164
UL https://hdl.handle.net/10630/38164
LA eng
NO Niu H, Alvarez-Alvarez I, Chen M. Artificial Intelligence: An Emerging Tool for Studying Drug-Induced Liver Injury. Liver Int. 2025;45(3):e70038
NO https://openpolicyfinder.jisc.ac.uk/id/publication/11895
NO This study was supported by grants from Instituto de Salud Carlos III, cofunded by Fondo Europeo de Desarrollo Regional - FEDER, cofunded by the European Union (grant number: PI21/01248; PID2022-140169OB-C21, PT23/00137) and by the Agencia Española de Medicamentos y Productos Sanitarios. CIBERehd and Plataforma de Investigación Clinica are funded by ISCIII. HN holds a postdoctoral research contract funded by Junta de Andalucía (POSTDOC_21_00780). Funding for open access charge: Universidad de Málaga/CBUA. The funding sources had no involvement in the writing of the report or in the decision to submit the manuscript for publication.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026